• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外冲击波治疗中的剂量-效应关系:体外冲击波治疗的最佳参数。

The dose-effect relationship in extracorporeal shock wave therapy: the optimal parameter for extracorporeal shock wave therapy.

机构信息

Department of Orthopedics, Sixth People's Hospital, Shanghai JiaoTong University, Shanghai, China.

出版信息

J Surg Res. 2014 Jan;186(1):484-92. doi: 10.1016/j.jss.2013.08.013. Epub 2013 Sep 3.

DOI:10.1016/j.jss.2013.08.013
PMID:24035231
Abstract

BACKGROUND

Extracorporeal shock wave therapy (ESWT) has been demonstrated to have the angiogenic effect on ischemic tissue. We hypothesize that ESWT exerts the proangiogenesis effect with an energy density-dependent mode on the target cells.

MATERIALS AND METHODS

Endothelial progenitor cells (EPCs) of rats were obtained by cultivation of bone marrow-derived mononuclear cells. EPCs were divided into five groups of different energy densities, and each group was furthermore subdivided into four groups of different shock numbers. Thus, there were 20 subgroups in total. The expressions of angiogenic factors, apoptotic factors, inflammation mediators, and chemotactic factors were examined, and the proliferation activity was measured after ESWT.

RESULTS

When EPCs were treated with low-energy (0.04-0.13 mJ/mm(2)) shock wave, the expressions of endothelial nitric oxide synthase, angiopoietin (Ang) 1, Ang-2, and B-cell lymphoma 2 increased and those of interleukin 6, fibroblast growth factor 2, C-X-C chemokine receptor type 4, vascular endothelial growth factor a, Bcl-2-associated X protein, and caspase 3 decreased. stromal cell-derived factor 1 changed without statistical significance. When cells were treated with high-energy (0.16 mJ/mm(2)) shock wave, most of the expressions of cytokines declined except the apoptotic factors and fibroblast growth factor 2, and cells lead to apoptosis. The proliferation activity and the ratio of Ang-1/Ang-2 reached their peak values, when cells were treated with ESWT with the intensity ranging from 0.10-0.13 mJ/mm(2) and shock number ranging from 200-300 impulses. Meanwhile, a minimal value of the ratio of Bax/Bcl-2 was observed.

CONCLUSIONS

There is a dose-effect relationship in ESWT. The shock intensity ranging from 0.10-0.13 mJ/mm(2) and shock number ranging from 200-300 impulses were the optimal parameters for ESWT to treat cells in vitro.

摘要

背景

体外冲击波疗法(ESWT)已被证明对缺血组织具有血管生成作用。我们假设 ESWT 通过能量密度依赖模式对靶细胞发挥促血管生成作用。

材料与方法

通过培养骨髓源性单核细胞获得大鼠内皮祖细胞(EPCs)。EPCs 分为五组不同的能量密度,每组进一步分为四组不同的冲击次数。因此,共有 20 个子组。经 ESWT 治疗后,检测血管生成因子、凋亡因子、炎症介质和趋化因子的表达,并测量增殖活性。

结果

当 EPCs 接受低能量(0.04-0.13 mJ/mm²)冲击波治疗时,内皮型一氧化氮合酶、血管生成素 1(Ang1)、Ang2 和 B 细胞淋巴瘤 2 的表达增加,白细胞介素 6、成纤维细胞生长因子 2、C-X-C 趋化因子受体 4、血管内皮生长因子 a、Bcl-2 相关 X 蛋白和半胱天冬酶 3 的表达减少,基质细胞衍生因子 1 无统计学意义变化。当细胞接受高能量(0.16 mJ/mm²)冲击波治疗时,除凋亡因子和成纤维细胞生长因子 2 外,大多数细胞因子的表达下降,细胞发生凋亡。当细胞接受强度为 0.10-0.13 mJ/mm²、冲击次数为 200-300 次的 ESWT 治疗时,增殖活性和 Ang1/Ang2 比值达到峰值,同时观察到 Bax/Bcl-2 比值的最小值。

结论

ESWT 存在剂量效应关系。强度为 0.10-0.13 mJ/mm²、冲击次数为 200-300 次的冲击波是 ESWT 治疗细胞的最佳参数。

相似文献

1
The dose-effect relationship in extracorporeal shock wave therapy: the optimal parameter for extracorporeal shock wave therapy.体外冲击波治疗中的剂量-效应关系:体外冲击波治疗的最佳参数。
J Surg Res. 2014 Jan;186(1):484-92. doi: 10.1016/j.jss.2013.08.013. Epub 2013 Sep 3.
2
Shock wave treatment induces angiogenesis and mobilizes endogenous CD31/CD34-positive endothelial cells in a hindlimb ischemia model: implications for angiogenesis and vasculogenesis.冲击波治疗可促进后肢缺血模型中的血管生成并动员内源性 CD31/CD34 阳性内皮细胞:对血管生成和血管发生的影响。
J Thorac Cardiovasc Surg. 2013 Oct;146(4):971-8. doi: 10.1016/j.jtcvs.2013.01.017. Epub 2013 Feb 8.
3
The effect of autologous endothelial progenitor cell transplantation combined with extracorporeal shock-wave therapy on ischemic skin flaps in rats.自体内皮祖细胞移植联合体外冲击波疗法对大鼠缺血性皮瓣的影响。
Cytotherapy. 2014 Aug;16(8):1098-109. doi: 10.1016/j.jcyt.2014.02.013. Epub 2014 May 13.
4
Benefit of combined extracorporeal shock wave and bone marrow-derived endothelial progenitor cells in protection against critical limb ischemia in rats.联合体外冲击波和骨髓源性内皮祖细胞对防治大鼠肢体严重缺血的作用。
Crit Care Med. 2012 Jan;40(1):169-77. doi: 10.1097/CCM.0b013e31822d74d0.
5
Extracorporeal shock wave treatment in ischemic tissues: what is the appropriate number of shock wave impulses?体外冲击波治疗缺血组织:合适的冲击波冲击次数是多少?
J Reconstr Microsurg. 2010 Feb;26(2):117-21. doi: 10.1055/s-0029-1243296. Epub 2009 Dec 10.
6
Effect of extracorporeal shock wave therapy on osteoblastlike cells.体外冲击波疗法对成骨样细胞的影响。
Clin Orthop Relat Res. 2003 Aug(413):269-80. doi: 10.1097/01.blo.0000073344.50837.cd.
7
In Situ Activation of Penile Progenitor Cells With Low-Intensity Extracorporeal Shockwave Therapy.低强度体外冲击波疗法原位激活阴茎祖细胞
J Sex Med. 2017 Apr;14(4):493-501. doi: 10.1016/j.jsxm.2017.02.004. Epub 2017 Mar 1.
8
Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia.低能量冲击波促进内皮祖细胞募集:一种提高慢性后肢缺血细胞治疗疗效的新方法。
Circulation. 2006 Dec 19;114(25):2823-30. doi: 10.1161/CIRCULATIONAHA.106.628623. Epub 2006 Dec 4.
9
Optimal timing of extracorporeal shock wave treatment to protect ischemic tissue.体外冲击波治疗保护缺血组织的最佳时机。
Ann Plast Surg. 2011 Nov;67(5):539-44. doi: 10.1097/SAP.0b013e3182085880.
10
Effects of shock waves on tenocyte proliferation and extracellular matrix metabolism.冲击波对肌腱细胞增殖和细胞外基质代谢的影响。
Ultrasound Med Biol. 2008 May;34(5):841-52. doi: 10.1016/j.ultrasmedbio.2007.11.002. Epub 2008 Jan 25.

引用本文的文献

1
Biophysical aspects of mechanotransduction in cells and their physiological/biological implications in vocal fold vibration: a narrative review.细胞机械转导的生物物理方面及其在声带振动中的生理/生物学意义:一篇叙述性综述。
Front Cell Dev Biol. 2025 Jan 27;13:1501341. doi: 10.3389/fcell.2025.1501341. eCollection 2025.
2
Effectiveness of focused extracorporeal shock wave versus manual therapy in postpartum patients with sacroiliac joint dysfunction: a prospective clinical trial.聚焦体外冲击波与手法治疗产后骶髂关节功能障碍的疗效比较:一项前瞻性临床试验。
J Orthop Surg Res. 2024 Jan 3;19(1):28. doi: 10.1186/s13018-023-04491-0.
3
Extracorporeal Shock Wave Therapy for the Treatment of Musculoskeletal Pain: A Narrative Review.
用于治疗肌肉骨骼疼痛的体外冲击波疗法:一项叙述性综述。
Healthcare (Basel). 2023 Oct 26;11(21):2830. doi: 10.3390/healthcare11212830.
4
Effects of low-intensity extracorporeal shock wave therapy on lipopolysaccharide cystitis in a rat model of interstitial cystitis/bladder pain syndrome.低强度体外冲击波疗法对间质性膀胱炎/膀胱疼痛综合征大鼠模型脂多糖性膀胱炎的影响。
Int Urol Nephrol. 2024 Jan;56(1):77-86. doi: 10.1007/s11255-023-03770-3. Epub 2023 Sep 5.
5
Effects of Therapeutic Platelet-Rich Plasma on Overactive Bladder via Modulating Hyaluronan Synthesis in Ovariectomized Rat.富血小板血浆对去卵巢大鼠逼尿肌过度活动的治疗作用及其对透明质酸合成的调节作用。
Int J Mol Sci. 2023 May 4;24(9):8242. doi: 10.3390/ijms24098242.
6
Effectiveness of Extracorporeal Shockwave Therapy on Controlling Spasticity in Cerebral Palsy Patients: A Meta-Analysis of Timing of Outcome Measurement.体外冲击波疗法对控制脑瘫患者痉挛的有效性:结局测量时机的Meta分析
Children (Basel). 2023 Feb 9;10(2):332. doi: 10.3390/children10020332.
7
Application of extracorporeal shock wave therapy in nervous system diseases: A review.体外冲击波疗法在神经系统疾病中的应用:综述
Front Neurol. 2022 Aug 17;13:963849. doi: 10.3389/fneur.2022.963849. eCollection 2022.
8
Spasticity Management after Spinal Cord Injury: The Here and Now.脊髓损伤后的痉挛管理:现状与展望
J Pers Med. 2022 May 17;12(5):808. doi: 10.3390/jpm12050808.
9
Translational Applications of Extracorporeal Shock Waves in Dental Medicine: A Literature Review.体外冲击波在牙科医学中的转化应用:文献综述
Biomedicines. 2022 Apr 14;10(4):902. doi: 10.3390/biomedicines10040902.
10
Extracorporeal Shock Wave Therapy Combined with Platelet-Rich Plasma during Preventive and Therapeutic Stages of Intrauterine Adhesion in a Rat Model.大鼠模型中体外冲击波疗法联合富血小板血浆用于宫腔粘连预防和治疗阶段的研究
Biomedicines. 2022 Feb 17;10(2):476. doi: 10.3390/biomedicines10020476.